$1.530
0.000 (0.00%)收盤時
- 最高
- 1.570
- 開盤
- 1.490
- 成交量加權均價
- 1.53
- 成交量
- 12.87K
- 市值
- —
- 最低
- 1.490
- 成交金額
- 19.69K
- 企業價值/稅息折舊攤銷前利潤（TTM）
- 0.00
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities.
AI 分析 of SL Science Holding Ltd (SLBT)
持有SL Science Holding Ltd (SLBT) is not a good buy right now due to its current price of $1.53, which is significantly down 73.62% year-to-date. The RSI is at 37.199, indicating that the stock is currently oversold, but the forward P/E ratio is 0, suggesting a lack of earnings expectations. The recent positive news about glioblastoma treatment shows potential, but the company reported a net income loss of $29,122 in Q1 2026, highlighting ongoing financial struggles. The main risk is the extremely high debt to equity ratio of 882.89%, which poses a significant financial risk for investors.
估值指標
資訊
9.009-27NASDAQ.COMSL Science Holding Reports Positive Data for Glioblastoma Treatment
9.008-27NASDAQ.COMSL Science Holding Files New Drug Master File with FDA
9.008-27NewsfilterSL Science Files New Drug Master File with FDA
9.508-04NASDAQ.COMBiotech Stocks Surge with Significant Gains
- 8.507-17Newsfilter
SL Science Showcases γδ T Cell Therapy for Glioblastoma
SLBT 常見問題 —— 由 Alphio AI 解答
SL Science Holding Ltd is a Taiwan-based company mainly engaged in the research and development (R&D) of cell and gene therapies for cancer treatment and regenerative medicine. The Company develops investigational immune cell technologies, including gamma delta (γδ) T cells, Armed-T cells and exosome-based formulations, and operates through its biotechnology and oncology research activities. It operates in the Healthcare sector.
SL Science Holding Ltd (SLBT) is not a good buy right now due to its current price of $1.53, which is significantly down 73.62% year-to-date. The RSI is at 37.199, indicating that the stock is currently oversold, but the forward P/E ratio is 0, suggesting a lack of earnings expectations. The recent positive news about glioblastoma treatment shows potential, but the company reported a net income loss of $29,122 in Q1 2026, highlighting ongoing financial struggles. The main risk is the extremely high debt to equity ratio of 882.89%, which poses a significant financial risk for investors.
社群
更多 ↗暫無貼文
註冊或登入後參與討論本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。